The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer.
IF: 6.208
Cited by: 13


Immunotherapy has improved patient survival in many types of cancer, but for prostate cancer, initial results with immunotherapy have been disappointing. Prostate cancer is considered an immunologically excluded or cold tumor, unable to generate an effective T-cell response against cancer cells. However, a small but significant percentage of patients do respond to immunotherapy, suggesting that some specific molecular subtypes of this tumor may have a better response to checkpoint inhibitors. Recent findings suggest that, in addition to their function as cancer genes, somatic mutations of PTEN, TP53, RB1, CDK12, and DNA repair, or specific activation of regulatory pathways, such as ETS or MYC, may also facilitate immune evasion of the host response against cancer. This review presents an update of recent discoveries about the role that the common somatic mutations can play in changing the tumor microenvironment and immune response against prostate cancer. We describe how detailed molecular genetic analyses of the tumor microenvironment of prostate cancer using mouse models and human tumors are providing new insights into the cell types and pathways mediating immune responses. These analyses are helping researchers to design drug combinations that are more likely to target the molecular and immunological pathways that underlie treatment failure.


Spatial Transcriptomics
checkpoint blockade
genomic instability
immune evasion
innate and adaptive immune system
mouse models of cancer
single-cell transcriptomics
spatial imaging
tumor suppressor genes

MeSH terms

Clinical Trials as Topic
Genes, Neoplasm
Neoplasms, Experimental
Prostatic Neoplasms
Single-Cell Analysis
Spatial Analysis
Tumor Microenvironment


Melo, Camila Morais
Vidotto, Thiago
Chaves, Luiz Paulo
Lautert-Dutra, William
Reis, Rodolfo Borges Dos
Squire, Jeremy Andrew

Recommend literature

Similar data